Drugs

Which immunosuppressive agents are reported to be successful in treating severe ocular Behcets disease? • Topical (anterior uveitis), intraocular, and systemic corticosteroids (posterior involvement). • Azathioprine, 2.5 mg/kg per day should be combined with corticosteroids for posterior involvement (uveitis, retina, optic nerve). • Anti-TNFα therapy: Infliximab (5 mg/kg IV) is best. Use in combination with azathioprine or other …

Which immunosuppressive drugs are successful in treating severe ocular Behcets disease Read More »

Treatment for Behcets disease What other therapies can be useful in Behcets disease? • Arthritis: colchicine. If refractory, use corticosteroids, azathioprine, methotrexate, TNF-α antagonists. Interferon-α and sulfasalazine have also been used. • CNS: corticosteroids, azathioprine, interferon-α, cyclophosphamide, chlorambucil, TNF-α antagonists. Do not use cyclosporine unless necessary to treat coexisting ocular disease. • Gastrointestinal: corticosteroids, sulfasalazine, azathioprine, TNF-α antagonists. …

Treatment for Behcets disease Read More »

Which drugs are reported to be successful in treating the mucocutaneous lesions of Behcets syndrome? • Topical triamcinolone acetonide cream (0.1% in Orabase) or dexamethasone elixir (0.5 mg/5 mL) swish for 5 to 10 minutes and spit (but do not rinse) three times daily. • Topical pimecrolimus in combination with topical corticosteroids. • Topical sulcrafate (1 g/5 mL …

Which drugs are reported to be successful in treating the mucocutaneous lesions of Behcets syndrome Read More »

Safety of RTX when used to treat mixed cryoglobulinemic vasculitis Overall, safety is similar when compared with other treatments. Serum sickness occurs in ∼1% of cases and is usually mild. One study suggested that the administration of RTX 1 g every 2 weeks is more commonly associated with severe systemic reactions (e.g., exacerbation of vasculitis) …

Safety of RTX when used to treat mixed cryoglobulinemic vasculitis Read More »

Use of AV agents and RTX in the treatment of HCV associated mixed cryoglobulinemic vasculitis AV agents should be considered in all patients with HCV-associated MC. Historically, interferon-based regimens demonstrated response rates of 30% to 80% in MC, but use was commonly limited due to contraindications, side effects (interferon-α may exacerbate vasculitis manifestations), and slow …

Use of AV agents and RTX in the treatment of HCV associated mixed cryoglobulinemic vasculitis Read More »

Treatment options for mixed cryoglobulinemic vasculitis Removal of the antigenic stimulus is the primary goal. In HCV-associated mixed cryoglobulinemic vasculitis, this involves use of standard AV regimens, whereas in malignancy, other infections, and autoimmune diseases, appropriate treatment of these conditions is warranted. Immunosuppression is used to directly control the vasculitis and associated tissue damage. Most …

Treatment options for mixed cryoglobulinemic vasculitis Read More »

How is Eosinophilic Granulomatosis with Polyangiitis treated? The treatment of choice is GCs. Patients with a FFS of 0 may be managed with GCs alone. However, flares occur in 35% when GCs are tapered. Patients with poor prognostic factors (FFS ≥1) need GCs (60–80 mg/day divided dose), and cyclophosphamide (monthly pulse) should be considered as …

How is Eosinophilic Granulomatosis with Polyangiitis treated Read More »